Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IACS-13909 |
Trade Name | |
Synonyms | IACS13909|IACS 13909 |
Drug Descriptions |
IACS-13909 binds to and inhibits the phosphatase activity of Shp2, inhibits signaling through the MAPK pathway, potentially inhibiting cell proliferation and tumor growth (PMID: 32928921). |
DrugClasses | SHP2 Inhibitor 20 |
CAS Registry Number | 2160546-07-4 |
NCIT ID |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
IACS-13909 | IACS-13909 | 1 | 0 |
IACS-13909 + Osimertinib | IACS-13909 Osimertinib | 0 | 0 |
IACS-13909 + Palbociclib + Trametinib | IACS-13909 Palbociclib Trametinib | 0 | 0 |